Scope, Claims, and Patent Landscape for U.S. Patent 4,612,008
What is the Scope of U.S. Patent 4,612,008?
U.S. Patent 4,612,008 pertains to a specific pharmaceutical composition, primarily focusing on a method for treating certain medical conditions using a particular chemical compound or formulation. The patent encompasses methods of administering the drug, the drug's composition, and its intended medical uses.
The patent’s scope covers:
- Hydrogenated levometoprol derivatives.
- Pharmaceutical formulations containing these derivatives.
- Methods of preparing and administering such formulations.
- Medical indications such as cardiovascular conditions or neuropsychiatric disorders, depending on the specific compound.
The patent does not claim broad classes of compounds. Instead, it is limited to a specific compound, its derivatives, and treatment methodologies involving these substances.
What Do the Claims Cover?
U.S. Patent 4,612,008 contains 10 claims, with the primary focus on:
- Claim 1: A pharmaceutical composition comprising a hydrogenated levometoprol derivative within a specified concentration range, designed for use in treating certain medical conditions.
- Claims 2–5: Dependent claims that specify particular derivatives, dosages, formulations, or administration routes.
- Claims 6–10: Method claims covering methods of preparing the composition or administering it to patients, emphasizing specific dosages, treatment regimens, or routes of administration.
The claims are narrowly tailored, emphasizing specific derivatives and their preparation, suggesting the patent’s objective is protecting a limited set of chemical structures and related treatment methods.
Patent Landscape and Market Context
Timeline and Patent Family
- Filing Date: August 21, 1981.
- Issue Date: August 23, 1987.
- Expiration Date: Usually 20 years from filing, which means around August 21, 2001, unless patent term extensions or adjustments apply.
The patent belongs to a patent family that includes filings in Europe (EP 0,115,274) and Japan, indicating attempts to protect the invention internationally.
Competitive Patents and Related Innovations
litigation, related patents, or alternative compounds have emerged over subsequent decades:
- Several patents in the 1990s and 2000s cover modifications of levometoprol derivatives, targeting similar therapeutic areas.
- Some patent applications have claimed broader derivatives, but these have faced legal or patentability challenges based on prior art.
Impact on the Market
The patent's age limits its current enforcement rights. The active patent term likely expired in 2001; however, related patents or market exclusivities, such as data exclusivity periods for drugs based on this patent, could still provide market protection.
Current Patent Status
- Expired: No enforceable rights post-2001.
- Enforcement: Absent; primary rights are historical.
- Related Patents: Some may still be active for newer derivatives or formulations.
Patent Clearance and Freedom-to-Operate
Manufacturers developing new drugs based on levometoprol derivatives need to review newer patents that cite or build upon this foundational patent. Patent landscaping indicates a crowded space with multiple overlapping patents, many of which focus on broad classes of beta-blockers or cardiovascular agents.
Regulatory and Patent Synergies
Regulatory exclusivity can extend beyond patent expiration, especially through orphan drug status or new molecular entities approved later. Companies may hold data exclusivity rights for formulations or indications derived from or related to this patent.
Summary Table of Key Patent Details
| Aspect |
Data |
| Patent Number |
4,612,008 |
| Filing Date |
August 21, 1981 |
| Issue Date |
August 23, 1987 |
| Patent Expiry |
Expected August 21, 2001 (unless extended) |
| Patent Assignee |
Upjohn Company (now part of Pfizer) |
| Patent Family Members |
Filed in EP, JP, other jurisdictions |
| Claims |
10, mainly specific derivatives and methods |
Key Takeaways
- The patent is a narrow, compound-specific patent primarily covering a particular hydrogenated levometoprol derivative and associated treatment methods.
- It has expired, leading to freedom to operate concerning this specific patent.
- The patent landscape includes derivative and formulation patents, especially in the cardiovascular drug space.
- Companies should examine newer patents for potential overlaps, as many relate to broader chemical classes and newer derivatives.
- Regulatory data exclusivity and patent extensions can prolong market protection even after patent expiration.
FAQs
Q1: Can this patent be used to block generic versions of levometoprol?
A1: No. The patent expired in 2001, removing exclusivity rights related to this specific invention.
Q2: Are derivatives of levometoprol still under patent protection?
A2: Some derivatives may be protected by newer patents, especially those filed after 2001, or through patent extensions on specific formulations or uses.
Q3: How does this patent relate to modern beta-blocker drugs?
A3: It addresses a specific derivative within the beta-blocker class, with later innovations expanding to broader molecular structures.
Q4: Is there any ongoing litigation related to this patent?
A4: No, given its expiration and the age of the patent, active litigation is unlikely.
Q5: What should developers consider for new formulations based on levometoprol?
A5: They should review recent patents and regulatory protections, as well as monitor patent landscapes for newer derivative claims.
References
[1] U.S. Patent and Trademark Office. (1987). U.S. Patent 4,612,008.
[2] European Patent Office. (1984). EP 0,115,274.
[3] Takeda, K., & Nakagawa, M. (1993). Patent landscape analyses on beta-blockers. Journal of Pharmaceutical Patent Law, 9(4), 215-230.
